← All trials
NCT04784247
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 18, 2021
- Primary completion
- Mar 31, 2024
- Completion date
- Mar 31, 2024
- First posted
- Mar 5, 2021
- Last posted
- Jul 9, 2021
- Enrollment
- 50
- Arms / groups
- 5 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Memorial Sloan-Kettering Cancer CenterLead sponsor
- MerckCollaborator
- Memorial Sloan-Kettering Cancer CenterOverall official - principal investigator
- The Parker InstituteCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.